NovoCure (NVCR) Q3 Results Sharpen The Profitability Debate

NovoCure stock barely budged after Q3 2026 earnings, inching up about 0.2% to US$13.14 despite a report that was anything but flat. Traders focused on a bruised 30 day return, down about 18%. Longer term holders will likely zero in on something different.

The headline is simple. NovoCure delivered record quarterly revenue of US$193.4 million and turned adjusted EBITDA positive at US$16 million while still reporting a net loss. In the short term, that mix can look messy. Over a multi year horizon, it raises a sharper debate about valuation and the path to real profitability.

Like the revenue momentum at NovoCure but uneasy about an earnings story that still hinges on adjusted metrics and ongoing net losses? Consider exploring 30 resilient stocks with low risk scores for companies that combine steadier profitability with lower risk profiles.

Q3 2026 Earnings Summary

• Total Revenue (Q3 2026 vs Q3 2025): US$193.4 million vs. US$167.2 million (up roughly 16%)
• Net Income/Loss (Q3 2026 vs Q3 2025): Net loss of US$10.4 million vs. net loss of US$37.3 million (loss narrowed materially)
• Basic EPS (Q3 2026 vs Q3 2025): loss of US$0.09 per share vs. loss of US$0.33 per share (per share loss reduced)
• Gross Margin (Q3 2026 vs Q3 2025): 77% vs. 73% (margin improved)

NovoCure hit positive adjusted EBITDA and raised full-year guidance. Ask Charlie what NovoCure’s path to full profitability looks like.

NovoCure’s Bull Case Meets Concrete Milestones

The optimistic view around NovoCure hinges on disciplined spending and expanding TTFields use beyond GBM into pancreatic and lung cancer. That ambition is captured here.

"The main factor that needs to go right is continued adoption and reimbursement of Optune Gio, Lua and Pax, supported by disciplined R&D and operating expenses that remain at or below current levels."

Q3 results speak directly to this. Active GBM patients reached 4,729, Optune Lua and Pax together produced roughly US$12 million in revenue, and Japan is already driving Lua uptake. On costs, high 70s gross margin held, while selling and marketing and G&A both declined year over year, even as R&D edged up, keeping adjusted EBITDA in positive territory.

The price and this Narrative do not agree. → Uncover what this Narrative says NovoCure is actually worth.

NovoCure Bear Case: Profit Path Still Fragile

The cautious view argues that NovoCure may struggle to turn TTFields adoption into durable, profitable earnings while holding the cost line.

"Despite NovoCure tightening R&D and G&A and aiming for breakeven adjusted EBITDA by 2026, the company still reported a Q2 2026 GAAP net loss of US$16 million. Incremental spending on commercial rollouts or new label broadening work could delay a shift to consistent net income and keep overall earnings volatile."

Q3 shows adjusted EBITDA in the black and GAAP losses shrinking, which helps. Yet R&D still edged higher, LUNAR 2 remains a heavy commitment, and Pax launch friction confirms that extra commercial spend may be needed. The profitability concern is eased but not disproved.

Hunt Quiet Disconnects In Plain Sight

NovoCure just showed how earnings progress and a muted share reaction can drift apart. The real opportunity is spotting stocks that could be undervalued before that gap closes.

• Company 1 - 31% below our estimate - targets long term digital infrastructure choke points where data is processed, connected, secured and managed at scale.
• Company 2 - 37% below our estimate - reshapes a regional bank through lower cost deposits, digital upgrades and acquisitions to lift efficiency and earnings durability.
• Company 3 - 19% below our estimate - scales a teahouse network as overseas outlets grow and franchise economics tighten around healthier same store spending and supply chain support.

That is three of the list. See the full list of 29 companies trading below our fair value estimates →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com